Photothermal therapy (PTT), particularly in the near-infrared-II (NIR-II) range, has attracted widespread attention over the past years. However, the accompanied inflammatory responses can result in undesirable side effects and contribute to treatment ineffectiveness. Herein, we introduced a novel biodegradable nanoplatform (CuS/HMON-PEG) capable of PTT and hydrogen sulfide (H 2 S) generation, aimed at modulating inflammation for improved cancer treatment outcomes. The embedded ultrasmall copper sulphide (CuS) nanodots (1-2 nm) possessed favorable photoacoustic imaging (PAI) and NIR-II photothermal capabilities, rendering CuS/HMON-PEG an ideal phototheranostic agent. Upon internalization by 4T1 cancer cells, the hollow mesoporous organosilica nanoparticle (HMON) component could react with the overproduced glutathione (GSH) to produce H 2 S. In addition to the anticipated photothermal tumor ablation and H 2 S-induced mitochondrial dysfunction, the anti-inflammatory regulation was also been demonstrated by the downregulation of tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1beta (IL-1β). More importantly, the modulation of inflammation also promoted wound healing mediated by PTT. This work not only presents a H 2 S-based nanomodulator to boost NIR-II PTT but also provides insights into the construction of novel organic/inorganic hybrid nanosystems.
Keyphrases
- photodynamic therapy
- drug delivery
- fluorescence imaging
- drug release
- cancer therapy
- papillary thyroid
- fluorescent probe
- high resolution
- oxidative stress
- rheumatoid arthritis
- anti inflammatory
- squamous cell
- cell proliferation
- squamous cell carcinoma
- lymph node metastasis
- metal organic framework
- gold nanoparticles
- childhood cancer
- water soluble
- combination therapy
- reduced graphene oxide
- room temperature
- highly efficient
- perovskite solar cells